Dailypharm Live Search Close

MOHW-Roche have difficulty discussing resupply of Madopar

By Lee, Jeong-Hwan | translator Kim, Jung-Ju

23.08.26 05:50:39

°¡³ª´Ù¶ó 0
Roche expresses its position on how it cannot resupply the drug in Korea due to the facility cost required to manufacture Korea¡¯s supply

The government proposes measures, such as informing Roche about drug price increase procedures


The Ministry of Health and Welfare seems to be having difficulty bringing in Madopar, a Parkinson's disease drug that had withdrawn from the domestic market, back to Korea. The MOHW had previously announced that it would make efforts to resupply Madopar in Korea.

Roche Korea is known to have refused to supply Madopar Tab to Korea, citing how additional administrative procedures are required to resupply Madopar and that significant expenses are required to produce quantities for export to Korea.

On the 25th, the MOHW responded, "We will find a way to solve the patient's difficulties, including resupply," to a written inquiry submitted by Rep Eun-mi Kang, a member of the Justice Party and

Lee, Jeong-Hwan(junghwanss@dailypharm.com)
If you want to see the full article, please JOIN US (click)